|
You can create a custom page of the scientific sessions and compose a personal
Program.
Click on the 
icon near the session name to add it to your personal Program.
|
Poster Walk 4: Rotavirus
|
|
Chairperson: Carlo Giaquinto, Italy |
|
10:30 |
Nosocomial rotavirus infections in a pediatric unit in Paris during four successive winter seasons
E. MARC 1, S. Biscardi 1, M. Soulier 1, P. Lebon 1, D. Gendrel 1France
|
|
10:40 |
Molecular characterization of a new variant of rotavirus P[8]G9 predominant in a sentinel-based survey in Central Italy
F. ANSALDI 1, B. Pastorino 1, L. Valle 1, P. Durando 1, F. Banfi 1, P. Tucci 2, P. Biasci 2, R. Gasparini 1, G. Icardi 1Italy
|
|
10:50 |
Rotavirus genotypes circulating in Portugal
F.M. RODRIGUES 1, C. Pereira 1, M.C. Alves 1, M.T. Dionisio 1, L. Januario 1, L. Lemos 1Portugal
|
|
11:00 |
Safety and immunogenicity of concomitant use of the pentavalent rotavirus vaccine (RotaTeq™) and oral poliovirus vaccine (OPV)
M. CIARLET 1, R. Sani-Grosso 1, G. Yuan 2, G. Liu 2, P.M. Liu 1, K.M. Gottesdiener 1, F. Schodel 1USA
|
|
11:10 |
Burden and costs of severe rotavirus disease in Denmark
T.K. FISCHER 1,2, N.M. Nielsen 1, J. Wohlfahrt 1, A. Paerregaard 3Denmark
|
|
11:20 |
Rotavirus genotypes in Europe 2004–2005: the REVEAL study
P. VAN DAMME 1, C. Giaquinto 2, M. Maxwell 3, P. Todd 4, M. Van Der Wielen 1Belgium; Italy; UK
|
|
11:30 |
Population-level impact of vaccination against rotavirus disease using a mathematical transmission model
T. VAN EFFELTERRE 1, C. Newbern 1, S. Debrus 1, M. Soriano-Gabarro 1Belgium
|
|
11:40 |
Human rotavirus vaccine rotarix ™ is highly efficacious in Europe during the first two years of life
T. VESIKARI 1, A. Karvonen 1, R. Prymula 2, V. Schuster 3, J.C. Tejedor 4, R. Cohen 5, S. Damaso 6, F. Meurice 6, H.H. Han 6Finland; Czech Republic; Germany; Spain; France; Belgium
|
Back
|
